Waddington-Cruz, Márcia
Schmidt, Hartmut
Botteman, Marc F.
Carter, John A. http://orcid.org/0000-0001-8539-5352
Stewart, Michelle
Hopps, Markay
Fallet, Shari
Amass, Leslie
Funding for this research was provided by:
Pfizer
Article History
Received: 30 March 2018
Accepted: 8 January 2019
First Online: 8 February 2019
Authors’ information
: MWC is Chief of the Neuromuscular Diseases Unit at the University Hospital, Federal University of Rio, Brazil; and has been overseeing the Familial Amyloid Polyneuropathy patient care clinic (CEPARM) at the hospital for over 20 years. MWC also serves as the chair of the Transthyretin Amyloidosis Outcomes Survey (THAOS).
: Not Applicable.
: Not Applicable.
: MS, MH, and LA are employees of Pfizer Inc. SF was an employee of Pfizer Inc. at the time this research was conducted. MFB is an employee of Pharmerit International, which received funding from Pfizer Inc. for study design, execution, analysis, and manuscript development. ASC was an employee of Pharmerit International at the time this research was conducted. JAC is an independent scientific consultant funded by Pharmerit International. HS and MWC were investigators for the study and were not financially compensated for collaborative efforts on publication-related activities. HS received support from FoldRx Pharmaceuticals, which was acquired by Pfizer Inc. in October 2010, as a clinical investigator. MWC received support from FoldRx Pharmaceuticals, which was acquired by Pfizer Inc. in October 2010, as a clinical investigator; has served on the scientific advisory board of Pfizer Inc.; received funding from Pfizer Inc. for scientific meeting expenses (travel, accommodations, and registration); and received research support from the National Institutes of Health. She currently serves on the THAOS (natural history disease registry) scientific advisory board.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.